Journal of Urban Health

, 86:909 | Cite as

Prevalence of Hepatitis C Infection in New York City, 2004

  • Katherine BornschlegelEmail author
  • Magdalena Berger
  • Renu K. Garg
  • Amado Punsalang
  • Christy M. McKinney
  • R. Charon Gwynn
  • Lorna E. Thorpe


Hepatitis C virus (HCV) is the leading cause of chronic liver disease in the United States. Accurate hepatitis C prevalence estimates are important to guide local public health programs but are usually unavailable to local health jurisdictions. National surveys may not reflect local variation, a particular challenge for urban settings with disproportionately large numbers of residents in high-risk population groups. In 2004, the New York City Department of Health and Mental Hygiene conducted the NYC Health and Nutrition Examination Survey, a population-based household survey of non-institutionalized NYC residents ages 20 and older. Study participants were interviewed and blood specimens were tested for antibody to HCV (anti-HCV); positive participants were re-contacted to ascertain awareness of infection and to provide service referrals. Of 1,786 participants with valid anti-HCV results, 35 were positive for anti-HCV, for a weighted prevalence of 2.2% (95% confidence interval [CI] 1.5% to 3.3%). Anti-HCV prevalence was high among participants with a lifetime history of injection drug use (64.5%, 95% CI 39.2% to 83.7%) or a lifetime history of incarceration as an adult (8.4%, 95% CI 4.3% to 15.7%). There was a strong correlation with age; among participants born between 1945 and 1954, the anti-HCV prevalence was 5.8% (95% CI 3.3% to 10.0%). Of anti-HCV positive participants contacted (51%), 28% (n = 5) first learned of their HCV status from this survey. Continued efforts to prevent new infections in known risk behavior groups are essential, along with expansion of HCV screening and activities to prevent disease progression in people with chronic HCV.


Hepatitis C Prevalence NYC New York City Survey Serosurvey 



We thank all the NYC HANES survey participants and staff, as well as Meredith Deutscher, MD, for her assistance with follow-up interviews.


  1. 1.
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144(10): 705-714.PubMedGoogle Scholar
  2. 2.
    Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 13(17): 2436-2441.PubMedGoogle Scholar
  3. 3.
    Bell BP, Manos MM, Zaman A, et al. The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance. Am J Gastroenterol. 2008; 103(11): 2727-2736.CrossRefPubMedGoogle Scholar
  4. 4.
    Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis. 2008; 12(3): 661-674.CrossRefPubMedGoogle Scholar
  5. 5.
    Frieden TR, Ozick L, McCord C, et al. Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis. Hepatology. 1999; 29(3): 883-888.CrossRefPubMedGoogle Scholar
  6. 6.
    McQuillan GM, Kruszon-Moran D, Kottiri BJ, Curtin LR, Lucas JW, Kington RS. Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988–1994. Am J Public Health. 2004; 94(11): 1952-1958.CrossRefPubMedGoogle Scholar
  7. 7.
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999; 341(8): 556-562.CrossRefPubMedGoogle Scholar
  8. 8.
    Des Jarlais DC, Diaz T, Perlis T, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol. 2003; 157(5): 467-471.CrossRefPubMedGoogle Scholar
  9. 9.
    Des Jarlais DC, Perlis T, Arasteh K, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS. 2005; 19(Suppl 3): S20-S25.CrossRefPubMedGoogle Scholar
  10. 10.
    Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994–2004. Clin Infect Dis. 2008; 46(12): 1852-1858.CrossRefPubMedGoogle Scholar
  11. 11.
    Spunt B. The current New York City heroin scene. Subst Use Misuse. 2003; 38(10): 1539-1549.CrossRefPubMedGoogle Scholar
  12. 12.
    Broz D, Ouellet LJ. Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend. 2008; 94(1–3): 221-233.CrossRefPubMedGoogle Scholar
  13. 13.
    Frank B. An overview of heroin trends in New York City: past, present and future. Mt Sinai J Med. 2000; 67(5–6): 340-346.PubMedGoogle Scholar
  14. 14.
    Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA. 2003; 289(8): 959-962.CrossRefPubMedGoogle Scholar
  15. 15.
    Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000; 31(3): 777-782.CrossRefPubMedGoogle Scholar
  16. 16.
    Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007; 14(2): 107-115.CrossRefPubMedGoogle Scholar
  17. 17.
    Thorpe LE, Gwynn RC, Mandel-Ricci J, et al. Study design and participation rates of the New York City Health and Nutrition Examination Survey, 2004. Prev Chronic Dis. 2006; 3(3): A94.PubMedGoogle Scholar
  18. 18.
    NCHS. National Center for Health Statistics. National Health and Nutrition Examination Survey: Interviewer Procedures Manual: March 2001; 2001.Google Scholar
  19. 19.
    CDC. Centers for Disease Control and Prevention. 2000 CDC Growth Charts for the United States: Methods and Development. Series report 11: Centers for Disease Control and Prevention; 2000: 210.Google Scholar
  20. 20.
    Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003; 52(RR-3): 1-13. 15; quiz CE11–14.PubMedGoogle Scholar
  21. 21.
    NCHS. NHANES 2003–2004 Documentation, Codebook, and Frequencies. Available at: 2007. Accessed on: January 2008.
  22. 22.
    Fuller CM, Ompad DC, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City. J Urban Health. 2004; 81(1): 20-24.PubMedGoogle Scholar
  23. 23.
    Hagan H, Des Jarlais DC. HIV and HCV infection among injecting drug users. Mt Sinai J Med. 2000; 67(5–6): 423-428.PubMedGoogle Scholar
  24. 24.
    Wang A, Book WM, McConnell M, Lyle T, Rodby K, Mahle WT. Prevalence of hepatitis C infection in adult patients who underwent congenital heart surgery prior to screening in 1992. Am J Cardiol. 2007; 100(8): 1307-1309.CrossRefPubMedGoogle Scholar
  25. 25.
    Weinbaum CM, Sabin KM, Santibanez SS. Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS. 2005; 19(Suppl 3): S41-S46.CrossRefPubMedGoogle Scholar
  26. 26.
    Fox RK, Currie SL, Evans J, et al. Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis. 2005; 41(2): 177-186.CrossRefPubMedGoogle Scholar
  27. 27.
    Rosenblum A, Nuttbrock L, McQuistion HL, Magura S, Joseph H. Hepatitis C and substance use in a sample of homeless people in New York City. J Addict Dis. 2001; 20(4): 15-25.CrossRefPubMedGoogle Scholar
  28. 28.
    Edlin B. Five Million Americans Infected with the Hepatitis C Virus: A Corrected Estimate (abstract). Paper presented at: American Association for the Study of Liver Diseases, 2005.Google Scholar

Copyright information

© The New York Academy of Medicine 2009

Authors and Affiliations

  • Katherine Bornschlegel
    • 1
    Email author
  • Magdalena Berger
    • 1
  • Renu K. Garg
    • 1
  • Amado Punsalang
    • 1
  • Christy M. McKinney
    • 1
  • R. Charon Gwynn
    • 1
  • Lorna E. Thorpe
    • 1
  1. 1.New York City Department of Health and Mental HygieneNew YorkUSA

Personalised recommendations